Atrial Fibrillation (AF) Clinical Trial
Official title:
Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation in a Real-World Cohort of Patients; BASEL Wearable Study
Verified date | February 2024 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Atrial fibrillation (AF) is the most common cardiac arrhythmia. This study is to assess the heart rhythm device accuracy of five cardiac wearable devices (Apple Watch, Kardia Mobile/Kardia Mobile 6L, Fitbit Sense, Samsung Galaxy Watch 3 and Withings Scanwatch, Withings SA, Model Number: HWA09) and its detection algorithms in identifying AF compared to a nearly simultaneously acquired physician-interpreted 12-lead ECG in a real world cohort of patients.
Status | Completed |
Enrollment | 312 |
Est. completion date | February 28, 2024 |
Est. primary completion date | January 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All consecutive patients undergoing electrophysiological study, pacemaker or implantable defibrillator (ICD) implantation or electric cardioversion at the University Hospital Basel are eligible for study participation and will be asked to participate Exclusion Criteria: - Use of a radial artery graft for coronary artery bypass grafting - Tattoos located on the skin of the wrist or forearm where wearable device will be placed - Patients receiving hemodialysis through arteriovenous fistula in the upper extremities - Patients with inability to communicate and comply with all study requirements - Patients who refused to participate in the trial |
Country | Name | City | State |
---|---|---|---|
Switzerland | Department of Cardiology, University Hospital Basel | Basel |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Heart rhythm device accuracy of cardiac wearable devices | Heart rhythm device accuracy of five cardiac wearable devices (Apple Watch, Kardia Mobile/Kardia Mobile 6L, Fitbit Sense, Samsung Galaxy Watch 3 and Withings Scanwatch Withings SA, Model Number: HWA09) in detecting AF compared to nearly simultaneously acquired physician interpreted 12-lead ECG. | one time assessment at baseline | |
Primary | Heart rhythm device accuracy of physician-interpreted iECG | Heart rhythm device accuracy of physician-interpreted iECG from a wearable device in detecting AF or SR compared to physician-interpreted 12-lead ECG | one time assessment at baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02630914 -
Medical and Surgical Hybrid Treatment of Atrial Fibrillation.
|
N/A | |
Completed |
NCT05410379 -
Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
|
||
Enrolling by invitation |
NCT05407415 -
KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation
|
N/A | |
Completed |
NCT04025710 -
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
|
N/A | |
Completed |
NCT01119274 -
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon
|
Phase 4 | |
Recruiting |
NCT03428048 -
Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
|
||
Recruiting |
NCT04298723 -
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
|
N/A | |
Completed |
NCT04218266 -
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
|
Phase 2 | |
Active, not recruiting |
NCT03732794 -
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
|
N/A | |
Active, not recruiting |
NCT04755283 -
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT04095559 -
Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O
|
||
Recruiting |
NCT05712200 -
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
|
Phase 3 | |
Recruiting |
NCT05955365 -
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
|
Phase 4 | |
Recruiting |
NCT05294445 -
From the Emergency Department Directly to Ablation of Atrial Fibrillation Study
|
N/A | |
Completed |
NCT02513316 -
Clinical Relevance of Microbleeds In Stroke
|
N/A |